重度二尖瓣环钙化患者经房间隔途径经导管二尖瓣置换术的早期结局
该多中心注册研究纳入12个中心的126例重度二尖瓣环钙化(MAC)行经房间隔途径经导管二尖瓣置换术(ViMAC)的患者,技术成功119例(94.4%),30天和1年全因死亡分别为16例和33例,基线中度及以上二尖瓣反流与1年死亡风险升高相关(HR 2.31,95%CI 1.07-4.99,P=.03)。
要点
- 经房间隔ViMAC技术成功率为94.4%(119/126),30天和1年全因死亡分别为16例和33例。
- 基线中度及以上二尖瓣反流与1年死亡风险升高相关(HR 2.31,95%CI 1.07-4.99,P=.03)。
- 8例(6.3%)发生左室流出道梗阻,其中7例未行室间隔心肌切除术。
核心结论
- 经房间隔ViMAC在该经选择的男性为主队列中安全可行;伴有显著二尖瓣反流的患者较单纯二尖瓣狭窄患者可能获益更少。
研究设计与样本
- 多中心注册研究,纳入美国及欧洲12个中心126例有症状二尖瓣功能障碍且重度MAC行ViMAC的患者,中位年龄76岁(IQR 70-82岁),女性28.6%,中位STS评分6.8%(IQR 4.0-11.4),中位随访89天(IQR 16-383.5)。
主要发现
- 61例(48.4%)为孤立性二尖瓣狭窄,25例(19.8%)为孤立性二尖瓣反流,40例(31.7%)为混合性二尖瓣病变。
- 技术成功119例(94.4%),30天和1年全因死亡分别为16例和33例。
- 30例(23.8%)同期行室间隔心肌切除术,8例(6.3%)发生左室流出道梗阻(其中7/8未行心肌切除术)。
- 118例有术后超声心动图的患者中5例(4.2%)存在中度以上瓣周漏。
- 多变量模型中,基线中度及以上二尖瓣反流与1年死亡风险升高相关(HR 2.31,95%CI 1.07-4.99,P=.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Implantation of a transcatheter valve-in-mitral annular calcification (ViMAC) has emerged as an alternative to traditional surgical mitral valve (MV) replacement. Previous studies evaluating ViMAC aggregated transseptal, transapical, and transatrial forms of the procedure, leaving uncertainty about each technique's advantages and disadvantages. Thus, we sought to evaluate clinical outcomes specifically for transatrial ViMAC from the largest multicenter registry to-date. METHODS: Patients with symptomatic MV dysfunction and severe MAC who underwent ViMAC were enrolled from 12 centers across the United States and Europe. Clinical characteristics, procedural details, and clinical outcomes were abstracted from the electronic record. The primary end point was all-cause mortality. RESULTS: We analyzed 126 patients who underwent ViMAC (median age 76 years [interquartile range {IQR}, 70-82 years], 28.6% female, median Society of Thoracic Surgeons score 6.8% [IQR, 4.0-11.4], and median follow-up 89 days [IQR, 16-383.5]). Sixty-one (48.4%) had isolated mitral stenosis, 25 (19.8%) had isolated mitral regurgitation (MR), and 40 (31.7%) had mixed MV disease. Technical success was achieved in 119 (94.4%) patients. Thirty (23.8%) patients underwent concurrent septal myectomy, and 8 (6.3%) patients experienced left ventricular outflow tract obstruction (7/8 did not undergo myectomy). Five (4.2%) patients of 118 with postprocedure echocardiograms had greater than mild paravalvular leak. Thirty-day and 1-year all-cause mortality occurred in 16 and 33 patients, respectively. In multivariable models, moderate or greater MR at baseline was associated with increased risk of 1-year mortality (hazard ratio, 2.31; 95% confidence interval, 1.07-4.99, P = .03). CONCLUSIONS: Transatrial ViMAC is safe and feasible in this selected, male-predominant cohort. Patients with significant MR may derive less benefit from ViMAC than patients with mitral stenosis only.
引用
- Brener MI, Hamandi M, Hong E, et al. Early outcomes following transatrial transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Thorac Cardiovasc Surg. 2022. PMID: 36153166. doi:10.1016/j.jtcvs.2022.07.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。